ANI PHARMACEUTICALS, INC Lease, Cost
ANI PHARMACEUTICALS, INC (ANIP) reported Lease, Cost of $3.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-27
- ANI PHARMACEUTICALS, INC lease, cost for the quarter ending 2022-12-31 was $294.00K, a 133.33% increase year-over-year.
- ANI PHARMACEUTICALS, INC lease, cost for the quarter ending 2022-09-30 was $254.00K, a 418.37% increase year-over-year.
- ANI PHARMACEUTICALS, INC lease, cost for the quarter ending 2022-06-30 was $197.00K, a 251.79% increase year-over-year.
- ANI PHARMACEUTICALS, INC lease, cost for the quarter ending 2022-03-31 was $192.00K, a 242.86% increase year-over-year.
- ANI PHARMACEUTICALS, INC lease, cost for fiscal 2025 was $3.55M, a 46.25% increase from fiscal 2024.
- ANI PHARMACEUTICALS, INC lease, cost for fiscal 2024 was $2.43M, a 7.73% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC lease, cost for fiscal 2023 was $2.25M, a 140.34% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC lease, cost for fiscal 2022 was $937.00K, a 225.35% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.55M 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $2.43M 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $2.25M 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $548.00K derived: sum of 2 quarters · filed 2025-02-28 | $745.00K derived: sum of 3 quarters · filed 2025-02-28 | $937.00K 10-K · filed 2025-02-28 |
| 2022-09-30 | $254.00K 10-Q · filed 2022-11-09 | $451.00K derived: sum of 2 quarters · filed 2022-11-09 | $643.00K 10-Q · filed 2022-11-09 | $769.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $197.00K 10-Q · filed 2022-08-08 | $389.00K 10-Q · filed 2022-08-08 | $515.00K derived: sum of 3 quarters · filed 2024-02-29 | $564.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $192.00K 10-Q · filed 2022-05-10 | $318.00K derived: sum of 2 quarters · filed 2024-02-29 | $367.00K derived: sum of 3 quarters · filed 2024-02-29 | $423.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $175.00K derived: sum of 2 quarters · filed 2024-02-29 | $231.00K derived: sum of 3 quarters · filed 2024-02-29 | $288.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $49.00K 10-Q · filed 2022-11-09 | $105.00K derived: sum of 2 quarters · filed 2022-11-09 | $162.00K 10-Q · filed 2022-11-09 | $240.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $56.00K 10-Q · filed 2022-08-08 | $113.00K 10-Q · filed 2022-08-08 | $191.00K derived: sum of 3 quarters · filed 2022-08-08 | $263.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $56.00K 10-Q · filed 2022-05-10 | $135.00K derived: sum of 2 quarters · filed 2022-05-10 | $207.00K derived: sum of 3 quarters · filed 2022-05-10 | $278.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $151.00K derived: sum of 2 quarters · filed 2022-03-15 | $222.00K derived: sum of 3 quarters · filed 2022-03-15 | $289.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $72.00K 10-Q · filed 2021-11-01 | $143.00K derived: sum of 2 quarters · filed 2021-11-01 | $210.00K 10-Q · filed 2021-11-01 | $278.00K derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | $71.00K 10-Q · filed 2021-08-06 | $138.00K 10-Q · filed 2021-08-06 | $206.00K derived: sum of 3 quarters · filed 2021-08-06 | $266.00K derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $67.00K 10-Q · filed 2021-05-07 | $135.00K derived: sum of 2 quarters · filed 2021-05-07 | $195.00K derived: sum of 3 quarters · filed 2021-05-07 | $254.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $128.00K derived: sum of 2 quarters · filed 2021-03-11 | $187.00K derived: sum of 3 quarters · filed 2021-03-11 | $250.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $60.00K 10-Q · filed 2020-11-05 | $119.00K derived: sum of 2 quarters · filed 2020-11-05 | $182.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $59.00K 10-Q · filed 2020-08-06 | $122.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $57.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |